FENNEC PHARMACEUTICALS INC (FENC) Fundamental Analysis & Valuation

NASDAQ:FENC • CA31447P1009

Current stock price

6.42 USD
+0.01 (+0.16%)
At close:
6.42 USD
0 (0%)
After Hours:

This FENC fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. FENC Profitability Analysis

1.1 Basic Checks

  • FENC had negative earnings in the past year.
  • FENC had a negative operating cash flow in the past year.
  • In the past 5 years FENC always reported negative net income.
  • FENC had negative operating cash flow in 4 of the past 5 years.
FENC Yearly Net Income VS EBIT VS OCF VS FCFFENC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M -10M 20M -20M

1.2 Ratios

  • FENC has a better Return On Assets (-13.81%) than 78.92% of its industry peers.
  • FENC's Return On Equity of -27.46% is fine compared to the rest of the industry. FENC outperforms 77.56% of its industry peers.
Industry RankSector Rank
ROA -13.81%
ROE -27.46%
ROIC N/A
ROA(3y)-24.83%
ROA(5y)-47.99%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
FENC Yearly ROA, ROE, ROICFENC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200 400 600 800

1.3 Margins

  • FENC has a better Gross Margin (91.57%) than 93.04% of its industry peers.
  • In the last couple of years the Gross Margin of FENC has remained more or less at the same level.
  • FENC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 91.57%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.92%
GM growth 5YN/A
FENC Yearly Profit, Operating, Gross MarginsFENC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -2K -4K -6K -8K -10K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. FENC Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for FENC has been increased compared to 1 year ago.
  • The number of shares outstanding for FENC has been increased compared to 5 years ago.
  • FENC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
FENC Yearly Shares OutstandingFENC Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M
FENC Yearly Total Debt VS Total AssetsFENC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M

2.2 Solvency

  • Based on the Altman-Z score of 0.50, we must say that FENC is in the distress zone and has some risk of bankruptcy.
  • FENC has a better Altman-Z score (0.50) than 61.12% of its industry peers.
  • FENC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.5
ROIC/WACCN/A
WACCN/A
FENC Yearly LT Debt VS Equity VS FCFFENC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M -10M 20M 30M

2.3 Liquidity

  • FENC has a Current Ratio of 6.37. This indicates that FENC is financially healthy and has no problem in meeting its short term obligations.
  • FENC's Current ratio of 6.37 is fine compared to the rest of the industry. FENC outperforms 63.06% of its industry peers.
  • FENC has a Quick Ratio of 6.23. This indicates that FENC is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 6.23, FENC is in the better half of the industry, outperforming 63.44% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.37
Quick Ratio 6.23
FENC Yearly Current Assets VS Current LiabilitesFENC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. FENC Growth Analysis

3.1 Past

  • FENC shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -486388759756013504.00%.
  • FENC shows a decrease in Revenue. In the last year, the revenue decreased by -6.09%.
  • Measured over the past years, FENC shows a very strong growth in Revenue. The Revenue has been growing by 204.69% on average per year.
EPS 1Y (TTM)-486388759756013500%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-66.67%
Revenue 1Y (TTM)-6.09%
Revenue growth 3Y207.19%
Revenue growth 5Y204.69%
Sales Q2Q%73.84%

3.2 Future

  • FENC is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 65.90% yearly.
  • The Revenue is expected to grow by 36.45% on average over the next years. This is a very strong growth
EPS Next Y349.87%
EPS Next 2Y148.48%
EPS Next 3Y138.9%
EPS Next 5Y65.9%
Revenue Next Year64.83%
Revenue Next 2Y50.43%
Revenue Next 3Y45.24%
Revenue Next 5Y36.45%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
FENC Yearly Revenue VS EstimatesFENC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 50M 100M 150M 200M
FENC Yearly EPS VS EstimatesFENC Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

4

4. FENC Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for FENC. In the last year negative earnings were reported.
  • FENC is valuated reasonably with a Price/Forward Earnings ratio of 9.52.
  • FENC's Price/Forward Earnings ratio is rather cheap when compared to the industry. FENC is cheaper than 97.68% of the companies in the same industry.
  • When comparing the Price/Forward Earnings ratio of FENC to the average of the S&P500 Index (22.84), we can say FENC is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 9.52
FENC Price Earnings VS Forward Price EarningsFENC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FENC Per share dataFENC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as FENC's earnings are expected to grow with 138.90% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y148.48%
EPS Next 3Y138.9%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. FENC Dividend Analysis

5.1 Amount

  • No dividends for FENC!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

FENC Fundamentals: All Metrics, Ratios and Statistics

FENNEC PHARMACEUTICALS INC

NASDAQ:FENC (4/2/2026, 8:23:24 PM)

After market: 6.42 0 (0%)

6.42

+0.01 (+0.16%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-24
Earnings (Next)05-11
Inst Owners49.88%
Inst Owner Change0%
Ins Owners2.88%
Ins Owner Change2.55%
Market Cap219.24M
Revenue(TTM)44.64M
Net Income(TTM)-9.74M
Analysts84.62
Price Target15.47 (140.97%)
Short Float %2.88%
Short Ratio4.99
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-185.87%
Min EPS beat(2)-380.11%
Max EPS beat(2)8.37%
EPS beat(4)2
Avg EPS beat(4)-128.87%
Min EPS beat(4)-380.11%
Max EPS beat(4)55.84%
EPS beat(8)3
Avg EPS beat(8)-155.39%
EPS beat(12)4
Avg EPS beat(12)-136.63%
EPS beat(16)6
Avg EPS beat(16)-108.59%
Revenue beat(2)1
Avg Revenue beat(2)2.53%
Min Revenue beat(2)-3.48%
Max Revenue beat(2)8.54%
Revenue beat(4)2
Avg Revenue beat(4)2.34%
Min Revenue beat(4)-3.48%
Max Revenue beat(4)8.54%
Revenue beat(8)3
Avg Revenue beat(8)-8.98%
Revenue beat(12)5
Avg Revenue beat(12)-5.98%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.09%
PT rev (3m)4.6%
EPS NQ rev (1m)-76.67%
EPS NQ rev (3m)-80.96%
EPS NY rev (1m)0%
EPS NY rev (3m)1.45%
Revenue NQ rev (1m)-11.72%
Revenue NQ rev (3m)-13.01%
Revenue NY rev (1m)-3.49%
Revenue NY rev (3m)-3.15%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 9.52
P/S 4.91
P/FCF N/A
P/OCF N/A
P/B 6.18
P/tB 6.18
EV/EBITDA N/A
EPS(TTM)-0.27
EYN/A
EPS(NY)0.67
Fwd EY10.51%
FCF(TTM)-0.37
FCFYN/A
OCF(TTM)-0.37
OCFYN/A
SpS1.31
BVpS1.04
TBVpS1.04
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -13.81%
ROE -27.46%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 91.57%
FCFM N/A
ROA(3y)-24.83%
ROA(5y)-47.99%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.92%
GM growth 5YN/A
F-Score1
Asset Turnover0.63
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.37
Quick Ratio 6.23
Altman-Z 0.5
F-Score1
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-486388759756013500%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-66.67%
EPS Next Y349.87%
EPS Next 2Y148.48%
EPS Next 3Y138.9%
EPS Next 5Y65.9%
Revenue 1Y (TTM)-6.09%
Revenue growth 3Y207.19%
Revenue growth 5Y204.69%
Sales Q2Q%73.84%
Revenue Next Year64.83%
Revenue Next 2Y50.43%
Revenue Next 3Y45.24%
Revenue Next 5Y36.45%
EBIT growth 1Y-322.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1736.51%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-146.23%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-146.23%
OCF growth 3YN/A
OCF growth 5YN/A

FENNEC PHARMACEUTICALS INC / FENC Fundamental Analysis FAQ

What is the fundamental rating for FENC stock?

ChartMill assigns a fundamental rating of 3 / 10 to FENC.


Can you provide the valuation status for FENNEC PHARMACEUTICALS INC?

ChartMill assigns a valuation rating of 4 / 10 to FENNEC PHARMACEUTICALS INC (FENC). This can be considered as Fairly Valued.


Can you provide the profitability details for FENNEC PHARMACEUTICALS INC?

FENNEC PHARMACEUTICALS INC (FENC) has a profitability rating of 2 / 10.


Can you provide the expected EPS growth for FENC stock?

The Earnings per Share (EPS) of FENNEC PHARMACEUTICALS INC (FENC) is expected to grow by 349.87% in the next year.